Trial Profile
Phase IV Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Epoetin zeta
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms FERASE
- 30 Nov 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Aug 2014 New trial record